Passage Bio (PASG) news
Recent news
Passage Bio - Dr. Smith to lead combined company, Matthew Patterson to chair board, Peter Colabuono to join board
AInvest Wire · Jun 24, 2026Passage Bio - shareholders to own 7%, Remix stockholders 93% of combined company
Passage Bio, Inc. (NASDAQ: PASG) has announced a 1-for-20 reverse stock split, effective July 14, 2025, to regain compliance with minimum bid price requirement . The move was approved by stockholders at the company’s 2025 annual meeting . The reverse stock split reduces outstanding shares from…
AInvest Wire · Jun 24, 2026Passage Bio - combined company to operate as Remix Therapeutics, trade as RMTX on Nasdaq
AInvest Wire · Jun 24, 2026Passage Bio - Remix secures $100 mln oversubscribed private placement financing
Passage Bio has announced the completion of a $100 million oversubscribed private placement financing, marking a significant milestone for the biotechnology company. The funding round reflects strong investor confidence in the company’s strategic direction and therapeutic pipeline. This latest…
AInvest Wire · Jun 24, 2026Passage Bio and Remix Therapeutics announce merger agreement
AInvest Wire · Jun 24, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.